THE ROLE OF POLYTABLETS (POLYPILL) IN THE TREATMENT OF CHRONIC CARDIOVASCULAR DISEASES
Main Article Content
Abstract
Keywords
Author Biographies
Николай Владимирович Абрамов,
senior lecturer, department of pharmacyВасилий Васильевич Кашталап,
doctor of medical sciences, docent, head of clinical cardiology department; professor of the department of cardiology and cardiovascular surgeryВиктор Андреевич Семенихин,
Viktor A. Semenikhin
doctor of medical sciences, professor, department of faculty therapy, occupational diseases and endocrinology
Сергей Николаевич Филимонов,
doctor of medical sciences, professor, Head of the Department of Human Ecology, Public Health and HealthcareArticle Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020; 76(25): 2982-3021. DOI: 10.1016/j.jacc.2020.11.010
Baumgartner A, Drame K, Geutjens S, Airaksinen M. Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review. Pharmaceutics. 2020; 12(2): 190. DOI: 10.3390/pharmaceutics12020190
Petrov AG, Abramov NV, Sedykh DYu, Kashtalap VV. A methodical approach to predicting the risk of non-compliance in patients with myocardial infarction. Complex problems of cardiovascular diseases. 2021; 10(4): 48-57. Russian (Методический подход к прогнозированию риска нонкомплаенса пациентов с инфарктом миокарда / А.Г. Петров, Н.В. Абрамов, Д.Ю. Седых, В.В. Кашталап //Комплексные проблемы сердечно-сосудистых заболеваний. 2021. Т. 10, № 4. С. 48-57.) DOI: 10.17802/2306-1278-2021-10-4-48-57
Khatib R, Patel N, Laverty U, Mcgawley G, McLenachan J, Shield S, Hall AS. Re-engineering the post-myocardial infarction medicines optimisation pathway: a retrospective analysis of a joint consultant pharmacist and cardiologist clinic model. Open Heart. 2018; 5(2): e000921. DOI: 10.1136/openhrt-2018-000921
Margolis KL, Bergdall AR, Crain AL, JaKa MM, Anderson JP, Solberg LI, et al. Comparing Pharmacist-Led Telehealth Care and Clinic-Based Care for Uncontrolled High Blood Pressure: The Hyperlink 3 Pragmatic Cluster-Randomized Trial. Hypertension. 2022; 79(12): 2708-2720. DOI: 10.1161/HYPERTENSIONAHA.122.19816
Morozova TE, Yudina IYu, Karnoukh KI, Shatskiy DA. Polypill in the prevention of cardiovascular diseases: evidence base, limitations and prospects (based on the report of the European Society for Hypertension). Consilium Medicum. 2017; 19(10): 8-12. Russian (Морозова Т.Е., Юдина И.Ю., Карноух К.И., Шацкий Д.А. Политаблетка в профилактике сердечно-сосудистых заболеваний: доказательная база, ограничения и перспективы (по материалам доклада Европейского общества по артериальной гипертензии) //Consilium Medicum. 2017. Т. 19, № 10. С. 8-12.) DOI: 10.26442/2075-1753_19.10.8-12
Huffman MD, Patel A. Polypills – A Central Strategy for Improving Cardiovascular Health. N Engl J Med. 2021; 384(3): 288-289. DOI: 10.1056/NEJMe2033310
Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med. 2021; 384(3): 216-228. DOI: 10.1056/NEJMoa2028220
Burns K, Turnbull F, Patel A, Peiris D. Opinions of community pharmacists on the value of a cardiovascular polypill as a means of improving medication compliance. Int J Pharm Pract. 2012; 20(3): 155-63. DOI: 10.1111/j.2042-7174.2011.00175.x
Mostaza JM, Suárez-Fernández C, Cosín-Sales J, Gómez-Huelgas R, Brotons C, Araujo FP, et al. Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial. BMC Cardiovasc Disord. 2022; 22(1): 560. DOI: 10.1186/s12872-022-03013-w
Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019; 394(10199): 672-683. DOI: 10.1016/S0140-6736(19)31791-X
Simon A, Dézsi CA. Treatment of Hypertensive and Hypercholesterolaemic Patients with the Triple Fixed Combination of Atorvastatin, Perindopril and Amlodipine: The Results of the CORAL Study. Adv Ther. 2019; 36(8): 2010-2020. DOI: 10.1007/s12325-019-01002-8
Simons LA, Chung E, Ortiz M. Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Curr Med Res Opin. 2017; 33(10): 1783-1787. DOI: 10.1080/03007995.2017.1367275
Liuzzo G, Patrono C. A one-size-fits-all polypill strategy for primary prevention in the era of precision medicine? Eur Heart J. 2021; 42(6): 561-562. DOI: 10.1093/eurheartj/ehaa1064
Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022; 387(11): 967-977. DOI: 10.1056/NEJMoa2208275
Kashtalap VV. Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation). Russian Journal of Cardiology. 2022; 27(11): 5285. Russian (Кашталап В.В. Медикаментозная терапия артериальной гипертонии и дислипидемии: возможности препарата Липертанс (на примере клинического наблюдения) //Российский кардиологический журнал. 2022. Т. 27, № 11. С. 5285.) DOI: 10.15829/1560-4071-2022-5285
Rao S, Jamal Siddiqi T, Khan MS, Michos ED, Navar AM, Wang TJ, et al. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials. Prog Cardiovasc Dis. 2022; 73: 48-55. DOI: 10.1016/j.pcad.2022.01.005